中國生物製藥(01177.HK)體液及能量補充劑“轉化糖注射液”獲藥品註冊批件
格隆匯 7 月 6日丨中國生物製藥(01177.HK)發佈公告,集團開發的體液及能量補充劑“轉化糖注射液”(商品名稱:豐海欣)已獲得國家藥品監督管理局頒發藥品註冊批件。該產品有5%(250ml:葡萄糖6.25g與果糖6.25g)和10%(250ml:葡萄糖12.5g與果糖12.5g)兩個規格,臨牀上可直接輸注為患者補充體液及能量,尤其適用於糖尿病患者以及燒創傷、術後等胰島素抵抗患者,還可用於藥物中毒和酒精中毒的治療。
豐海欣是由葡萄糖和果糖1:1混合而成,兼具二者特點——葡萄糖可迅速改善機體的血糖平衡;果糖繞過了葡萄糖代謝的限速酶,可直接快速補充能量,或轉化為糖原儲存,形成血糖緩釋長效供能。果糖不能透過血腦屏障,在外周組織供能,可避免脂肪和蛋白質的消耗;葡萄糖可透過血腦屏障給腦組織供能。二者互為補充,快速為人體補充能量。
集團的果糖注射液和混合糖注射液產品一直在市場享有高佔有率和良好口碑。豐海欣的獲批上市,將進一步豐富集團在圍手術期治療領域的產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.